Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172 , September 2010

Prolonged QTc Interval in Cancer Therapeutic Drug Development: Defining Arrhythmic Risk in Malignancy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Statement of Conflict of Interest: see page 171.

 Address reprint requests to Joanna Brell, MD, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd. EPN 2017, Bethesda, MD 20892.

PII: S0033-0620(10)00091-5

doi: 10.1016/j.pcad.2010.05.005

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172 , September 2010

Article Tools

* Image Usage & Resolution